StockNews.AI
GSK
StockNews.AI
175 days

Lost Money on GSK plc(GSK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

1. GSK faces a class action lawsuit over alleged securities fraud. The suit covers losses from Feb 2020 to Aug 2022. 2. Plaintiff alleges GSK misrepresented facts on Zantac withdrawal and NDMA risks. The claim contests regulator communications. 3. The lawsuit contends GSK knew NDMA sources for nearly 40 years before market withdrawal. This contradicts public regulatory assurances. 4. Investors can join the suit at no cost before the April 7, 2025 deadline. The case is managed by experienced securities litigation attorneys.

4m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit could dent investor confidence and add potential liability risks, similar to past litigation events that led to temporary stock declines in pharma companies facing legal challenges.

How important is it?

While the lawsuit may induce short-term negative sentiment and price volatility, historical cases in large pharma have shown that legal risks tend to be largely priced in unless settlements are substantial.

Why Short Term?

Litigation news typically causes near-term volatility, with potential settlements or procedural outcomes influencing short-term sentiment, though long-term fundamentals remain intact.

Related Companies

GSK
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") (NYSE: GSK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GSK investors who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=131762&wire=4 GSK investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market "[b]ased on information available at the time and correspondence with regulators." GSK also stated that it was "continuing with investigations into the potential source of NDMA." Defendants also assured investors that "GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients," findings that were "consistent with other ranitidine data published prior to 2019." Finally, defendants claimed that they could not "quantify or reliably estimate the liability." These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market. WHAT'S NEXT? If you suffered a loss in GSK during the relevant time frame, you have until April 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News